Intervention

Pimavanserin

ClinicalTrials.gov intervention label

Clinical trials17

Recruiting5

Common conditions12

Lead sponsors shown7

Clinical trials

17 shown

Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive DisorderNCT06592833 · 2025-02-25

Psilocybin Therapy for Depression in Parkinson's DiseaseNCT06455293 · 2024-08-19

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative DiseasesNCT05357612 · 2023-01-23

Pimavanserin vs. Quetiapine for Treatment of Parkinson's PsychosisNCT04373317 · 2022-10-24

Comparing Antipsychotic Medications in LBD Over TimeNCT05590637 · 2022-04-22

Pimavanserin for Sleep in Parkinson DiseaseNCT05796167 · 2023-01-27

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaNCT04531982 · 2020-08-05

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease PsychosisNCT04292223 · 2020-02-10

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose QuetiapineNCT04164758 · 2019-10-23

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentNCT04000009 · 2019-06-06

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentNCT03968159 · 2019-04-25

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and DepressionNCT03482882 · 2018-03-09

A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's DiseaseNCT03118947 · 2017-02-23

Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586 · 2017-01-01

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)NCT03018340 · 2016-12-01

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)NCT02970305 · 2016-11-04

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)NCT02970292 · 2016-10-26

Common conditions

Schizophrenia4 Adjunctive Treatment of Major Depressive Disorder3 Parkinson Disease3 Parkinson Disease Psychosis2 Parkinson's Disease Psychosis2 Agitation and Aggression in Alzheimer's Disease1 Dementia With Lewy Bodies1 Depression1 Major Depressive Disorder1 Neurodegenerative Diseases1 Parkinson's Disease1 Treatment of Depression in Adults With Parkinson's Disease (PD)1

Leading sponsors

ACADIA Pharmaceuticals Inc.11 Icahn School of Medicine at Mount Sinai1 Joshua Woolley, MD, PhD1 State University of New York - Downstate Medical Center1 The University of Texas Health Science Center at San Antonio1 VA Office of Research and Development1 Vanderbilt University Medical Center1

Trial status mix

COMPLETED8

RECRUITING5

TERMINATED3

WITHDRAWN1

Phase mix

PHASE27

PHASE35

PHASE44

EARLY_PHASE11

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.